Posts

Roche signs backloaded deal with Atavistik for allosteric CVRM drugs

on
Roche has signed a strategic research collaboration with Atavistik Bio potentially worth nearly $2 billion to discover oral small-molecule treatments for cardiovascular, renal and metabolic (CVRM) diseases. Atavistik will receive $70 million upfront and could earn up to $1.9 billion in research, development and commercial milestones, plus tiered royalties on any approved medicines. The partnership will use Atavistik’s AMPS platform to identify previously overlooked—or allosteric—binding pockets on proteins, potentially enabling more selective drugs against targets that have been difficult to modulate conventionally. Atavistik will lead discovery and early research. Roche will assume responsibility for preclinical and clinical development, regulatory work and commercialization. The agreement covers multiple targets, but the companies have not disclosed the number of programs or development timelines. Atavistik will continue pursuing its own hematology pipeline, including ATV-160...

AstraZeneca’s Breztri wins EU asthma approval, marking third major asthma clearance

on

Basecamp Research raises $140 million to advance AI-designed medicines

on

Merck’s $3B Eye-Drug Prospect Clears Pivotal Trial, but Safety Questions Remain

on

Lilly and InnoCare announce potential $3.35 billion, five-target drug-discovery deal

on

FDA Clears Elevar’s Lyrfigtu for FGFR2-Altered Bile Duct Cancer

on

GRAIL’s Galleri cancer blood test advances after mixed but favorable FDA panel vote

on

Trump FDA Nominee Supports Vaccine Safety but Treads Carefully on Mifepristone

on

Acadia’s Remlifanserin Misses Phase 2 Primary Endpoint but Advances in Alzheimer’s Psychosis

on

Kyverna says one-year CAR-T data strengthen FDA filing for stiff-person syndrome

on

ReCode CEO Suliman passes cystic fibrosis mission to Heather Clark

on

Roivant’s FcRn Drug Misses Phase 2b Goal in Cutaneous Lupus

on

FDA advisory panel backs GRAIL Galleri’s benefit-risk profile

on